Enhanced Pan-Antiallergy Vaccine System

Publication ID: 24-11857623_0006_PTD

Published: October 28, 2025

Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Enhanced Pan-Antiallergy Vaccine System,” Published Technical Disclosure No. 24-11857623_0006_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857623_0006_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,623.

Summary of the Inventive Concept

An improved pan-antiallergy vaccine system that enhances the immune response, monitors allergy symptoms, and adjusts vaccine dosage accordingly, providing a safer and more efficient treatment for allergies.

Background and Problem Solved

The original pan-antiallergy vaccine patent has limitations in terms of dosage adjustment and immune response enhancement. The new inventive concept addresses these limitations by introducing a wearable device and a computer program to monitor allergy symptoms and adjust vaccine dosage, as well as novel adjuvant compositions and modified protein constructs to enhance the immune response.

Detailed Description of the Inventive Concept

The enhanced pan-antiallergy vaccine system comprises a wearable device that continuously monitors a user's allergy symptoms, transmitting data to a computer program that adjusts the vaccine dosage accordingly. The system also includes novel adjuvant compositions that increase the production of IgE-neutralizing antibodies, and modified protein constructs with linker peptides that enhance the binding affinity to IgE. Additionally, the system includes a composition for treating allergies that combines the pan-antiallergy vaccine with a secondary medication that inhibits the release of histamine from mast cells.

Novelty and Inventive Step

The new claims introduce novel and non-obvious features, including the wearable device and computer program for dosage adjustment, novel adjuvant compositions, and modified protein constructs with linker peptides. These features provide a significant improvement over the original patent, enhancing the immune response, safety, and efficiency of the pan-antiallergy vaccine.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include different wearable device designs, alternative adjuvant compositions, and varying linker peptides in the modified protein constructs. Variations could also include different secondary medications for treating allergies, and integrating the system with electronic health records for more accurate patient profiling.

Potential Commercial Applications and Market

The enhanced pan-antiallergy vaccine system has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the treatment of allergies and asthma. The system's ability to monitor and adjust vaccine dosage in real-time, combined with its enhanced immune response and safety features, make it an attractive solution for patients and healthcare providers alike.

CPC Classifications

Section	Class	Group
A	A61	A61K39/395
A	A61	A61K2039/544
A	A61	A61K2039/555

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Immunology and vaccine development, specifically focusing on protein engineering, allergy treatment, and immunomodulatory constructs with expertise in computational protein design and immunological intervention strategies

Person of Ordinary Skill (PHOSITA) Profile

A researcher with advanced degrees in molecular biology or immunology, proficient in protein engineering techniques, computational modeling, and understanding of IgE-related immune responses, with access to bioinformatics tools and knowledge of vaccine development methodologies

Obviousness Rationale

A person skilled in the art would recognize that the PTD's variations represent predictable extensions of the source patent's core protein construct technology. The disclosed modifications, such as adding linker peptides and implementing adaptive dosage monitoring, are logical incremental improvements that leverage known techniques in protein engineering and personalized medicine. These variations demonstrate standard problem-solving approaches within immunological vaccine design that would be apparent to an ordinary practitioner.

Obvious Combinations & Variations

Source Patent Element

Protein construct with scaffold segment and motif segment targeting IgE

PTD Variation

Adding linker peptides to enhance binding affinity and modify protein construct structure

Obviousness Reasoning

Routine protein engineering technique using known computational modeling methods to optimize molecular interactions, representing a predictable variation within protein design principles

Source Patent Element

Extracellular adherence protein (EAP) domain as scaffold

PTD Variation

Implementing wearable monitoring device for adaptive vaccine dosage

Obviousness Reasoning

Integrating personalized medicine approaches with existing immunological constructs, utilizing standard IoT and data analytics techniques to create a responsive treatment system

Source Patent Element

Pan-antiallergy vaccine composition

PTD Variation

Adding secondary medication to inhibit histamine release from mast cells

Obviousness Reasoning

Combining known pharmacological interventions to enhance treatment efficacy, representing a standard approach in developing comprehensive therapeutic strategies

Source Patent Element

Computer modeling of protein scaffold modifications

PTD Variation

Machine learning algorithm for predicting allergic reaction likelihood

Obviousness Reasoning

Extending computational techniques from source patent to develop predictive diagnostic tools, using established machine learning approaches in medical research

Source Patent Element

Immunoglobulin E (IgE) targeting vaccine construct

PTD Variation

Novel adjuvant composition increasing IgE-neutralizing antibody production

Obviousness Reasoning

Applying standard immunological enhancement techniques to improve vaccine efficacy, representing a predictable optimization within vaccine development practices

35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857623 and the disclosed technical variations, a person having ordinary skill in the art would find the claimed innovations obvious and lacking inventive step. The published technical disclosure demonstrates that the claimed protein construct modifications, adaptive monitoring systems, and immunological interventions represent predictable extensions of existing vaccine development methodologies, thereby rendering subsequent claims obvious under 35 U.S.C. § 103.

Original Patent Information

Patent Number	US 11,857,623
Title	Pan-antiallergy vaccine
Assignee(s)	King Abdulaziz University